| Stereochemistry | RACEMIC |
| Molecular Formula | C21H27N3O3 |
| Molecular Weight | 369.4574 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1N(CCC2)C(=O)C3=CC=CN=C3
InChI
InChIKey=AUIHHZBJBKRDIE-UHFFFAOYSA-N
InChI=1S/C21H27N3O3/c1-15(2)23-13-18(25)14-27-19-9-3-6-16-8-5-11-24(20(16)19)21(26)17-7-4-10-22-12-17/h3-4,6-7,9-10,12,15,18,23,25H,5,8,11,13-14H2,1-2H3
Nicainoprol, also known as RU-42924, is calcium channel antagonist and a putative class I antiarrhythmic agent. Nicainoprol was shown to be useful in the prevention and treatment of arrhythmias associated with acute myocardial infarction. Nicainoprol had been in phase II clinical trials for the treatment of arrhythmia. However, this research has been discontinued.
CNS Activity
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Ventricular arrhythmia: doses of 200, 400, 600 mg three times daily in randomized order
Route of Administration:
Oral
The effects of nicainoprol (1-50 uM) on the transmembrane action potentials in isolated papillary muscles of the guinea pig was examined. Nicainoprol (greater than or equal to 5 uM) produced dose-dependent decreases in the maximal upstroke velocity (Vmax) of the action potential. Only the highest concentration (50 uM) decreased the amplitude and the overshoot of the action potential and shortened its duration at 50 or 90% repolarization levels (APD50, APD90). The potential at rest was not affected by any concentration tested (1-50 uM).
ACTIVE MOIETY
